Congress Materials - Multidisciplinary Head and Neck Cancers Symposium (MHNCS 2026)
2026 Multidisciplinary Head and Neck Cancers Symposium | Feb 19-21 | Palm Desert, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head & neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study
Ranee Mehra, Hsiang-Fong Kao, Hung-Ming Wang, Malwinder S. Sandhu, William Ince, Ajay Mehta, Marc Oliva, Ewa Pawlowska, Myung-Ju Ahn, Aarti Bhatia, Bhumsuk Keam, Paul Swiecicki, Ammar Sukari, Kiichiro Toyoizumi, Mark Wade, Emrullah Yilmaz, Sujay Shah, Kevin Harrington
Neoadjuvant and adjuvant amivantamab plus pembrolizumab in resectable, locally advanced HPV-unrelated head and neck squamous cell cancer: Cohort 6 of the phase 1b/2 OrigAMI-4 study
Douglas Adkins, Robert I Haddad, Paul Swiecicki, Ari Rosenberg, Jessica McDermott, Jessica Geiger, Siddarth Sheth, Kevin Harrington, Ravindra Uppaluri, Robert L Ferris, Nishant Agrawal, Shlomo Koyfman, Ken Tian, Joshua C Curtin, Kiichiro Toyoizumi, Isabelle Leconte, Emrullah Yilmaz, Sujay Shah, Barbara Burtness
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.